• Explore /
  • Poster
  • / Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Abstract Poster

Authors

null

Robin Kate Kelley

University of California San Francisco, San Francisco, CA

Robin Kate Kelley , Baek-Yeol Ryoo , Philippe Merle , Joong-Won Park , Luigi Bolondi , Stephen Lam Chan , Ho Yeong Lim , Ari David Baron , Francis Parnis , Jennifer Knox , Stéphane Cattan , Thomas Cheung Yau , Julie Lougheed , Steven Milwee , Anthony El-Khoueiry , Ann-Lii Cheng , Tim Meyer , Ghassan K. Abou-Alfa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer

Clinical Trial Registration Number

NCT01908426

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4088)

DOI

10.1200/JCO.2018.36.15_suppl.4088

Abstract #

4088

Poster Bd #

277

Abstract Disclosures

Similar Posters

First Author: Ghassan K. Abou-Alfa

First Author: Ghassan K. Abou-Alfa

First Author: Robin Kate Kelley

First Author: Robin Kate Kelley